Capital Research Global Investors grew its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) by 5.3% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 2,930,079 shares of the biopharmaceutical company’s stock after buying an additional 146,236 shares during […]
Rhenman & Partners Asset Management AB decreased its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) by 16.7% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 37,500 shares of the biopharmaceutical company’s stock after selling 7,500 […]
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Get Free Report) Director Amy W. Schulman sold 21,700 shares of Alnylam Pharmaceuticals stock in a transaction on Wednesday, May 29th. The stock was sold at an average price of $148.60, for a total value of $3,224,620.00. Following the transaction, the director now directly owns 8,436 shares of the company’s […]
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Get Free Report) has been given an average recommendation of “Moderate Buy” by the seventeen research firms that are presently covering the stock, MarketBeat reports. Seven equities research analysts have rated the stock with a hold recommendation and ten have given a buy recommendation to the company. The average 1 […]
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Get Free Report) has been assigned an average recommendation of “Moderate Buy” from the seventeen ratings firms that are presently covering the company, Marketbeat.com reports. Seven equities research analysts have rated the stock with a hold recommendation and ten have given a buy recommendation to the company. The average 1 […]